Cancer Medicines Drive Johnson & Johnson's Q1 Success: Surpassing Wall Street Projections

Johnson & Johnson (J&J) has posted a fantastic first quarter, with both sales and earnings surpassing Wall Street projections. The company's performance was spearheaded mainly by strong sales of its cancer medicines, especially the multiple myeloma medication Darzalex, generating $3.24 billion in sales—a 20% boost from last year.

Main Points:

Revenue and Profit: J&J's quarterly revenue came in at $21.89 billion, a 2.4% year-over-year increase, while adjusted earnings per share (EPS) were $2.77, beating analyst estimates of $2.59.

Cancer Drug Sales: Worldwide cancer drug sales jumped almost 18% to $5.68 billion, with Darzalex and Carvykti making major contributions.

MedTech and Pharmaceuticals: MedTech sales increased 2.5% to $8.02 billion, albeit short of expectations, while innovative medicines increased 2.3% to $13.87 billion.

Stelara Sales Fall: The psoriasis drug Stelara experienced sales drop more than 33% as a result of biosimilar competition.

Full-Year Guidance: J&J increased its sales guidance to $91.6 billion-$92.4 billion but reduced its EPS estimate to $10.50-$10.70.

This good beginning to the year supports J&J's leadership in healthcare, fueled by its diversified portfolio and innovative pipeline.

Source: Reuters, Investing.com, Business Wire